SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point of intense investor interest as the community awaits crucial Phase 3 data for its gene editing candidate and monitors the regulatory progress of its cardiac pipeline. With short interest levels remaining elevated, investors are actively debating the potential for a volatile move driven by upcoming clinical readouts and the possibility of a squeeze.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as investors react to a strategic partnership with OpenAI designed to accelerate drug discovery, while the community remains hyper-focused on the evolving competitive landscape against Eli Lilly's weight-loss pills. Conversations are dominated by debates over oral GLP-1 efficacy, long-term prescription velocity, and whether current technical levels signal a bottoming process or a value trap ahead of upcoming earnings.

APE fuels culture. Backed by the best club in the world and hundreds of thousands of holders worldwide, it’s the token for digital and IRL communities, builders, creators, collectors, gamers, and beyond.  APE is the native gas token of ApeChain and is available across multiple ecosystems including Ethereum, Arbitrum, Solana and HyperLiquid.z  ApeCoin's mission is is to supercharge its ecosystem by supporting high-quality builders &amp; reinforcing 3 core pillars: ApeChain, Bored Ape Yacht Club, and Otherside.

ApeCoin

ApeCoin is seeing a surge in investor attention and high-volume volatility, fueled by the launch of ApeChain and the influx of new on-chain projects. The community remains divided, with some traders highlighting the token's aggressive, flow-driven momentum while others express frustration over long-term price performance and historical dilution concerns.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending as investors aggressively debate the company's long-term commercial potential, fueled by community speculation surrounding its collaboration with major industry players like Synopsys and Applied Materials. While some discuss a potential breakout driven by its Gate-All-Around transistor technology and perceived short-squeeze setups, skeptical voices emphasize the lack of material revenue and concerns over recurring share offerings.

Dumb SEND IT

$DSIT is generating significant buzz among community members who are positioning the token as a high-momentum weekend runner, with active discussions focused on breaking through previous market cap milestones. Investors are coordinating social media engagement and highlighting developer-led airdrops to build momentum, while comparisons to other meme coin cycles drive speculation about its growth potential.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is facing downward pressure following a series of insider share sales, which has sparked frustration among retail investors already concerned by the company's long-term capital efficiency and commercial ramp-up. Despite the negativity, the community remains divided between those calling for a strategic buyout or management change and long-term believers who are leveraging the dip to accumulate shares based on the company's extensive gene-editing pipeline and substantial cash position.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing significant market interest driven by heavy insider buying from the CEO and growing community speculation regarding potential strategic partnerships with major AI firms. Investors are closely monitoring price action as the stock attempts to reclaim key technical levels, balancing optimism for an ad-tech rebound against ongoing concerns about institutional short positioning and broader software sector volatility.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is capturing significant market attention following its public debut, with investors closely watching the nuclear developer's strategic partnerships with major tech giants like Amazon to fuel AI infrastructure demand. While the community is debating the stock's valuation and long-term viability, the conversation is largely driven by high initial demand and the broader narrative surrounding the role of small modular reactors in solving energy bottlenecks.

Chip

CHIP is capturing significant market attention following its simultaneous listing on major trading platforms, including Robinhood, fueling investor debate over whether the token is a high-utility AI infrastructure asset or a volatile pump-and-dump cycle. While many traders are focused on the rapid volume growth and long-term potential of its GPU-backed lending model, others caution against chasing the price amid community requests for updated branding and concerns over potential market manipulation.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is seeing heightened investor attention as market participants track the upcoming Phase 2/3 clinical readout for tovecimig, a key bispecific antibody candidate for biliary tract cancer. The community is actively discussing the stock's binary event setup, weighing the potential for a breakthrough in a high-unmet-need oncology space against the inherent volatility typical of clinical-stage biotechs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>While the extension of the Israel-Lebanon ceasefire offered some relief, the lack of progress on a broader Iran deal kept oil prices elevated.</li><li>Intel surged over 20% pre-market, lifting semiconductor stocks after its AI business drove strong earnings.</li><li>On the economic front,&nbsp;traders will be watching the release of Durable Goods Orders data later this morning.</li></ul>U.S. stock futures were mixed early Friday as markets struggled to find direction after a previous choppy session. While there were relief signals with the extension of the Israel-Lebanon ceasefire, the lack of progress on a peace deal with Iran has kept a floor on oil prices, with Brent crude holding around $105/barrel.&nbsp;As of 4:00 a.m. ET on Friday: Dow and Russell 2000 futures fell 0.1%, S&amp;P 500 futures were flat with a positive bias and Nasdaq futures gained 0.5%.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained in the ‘bullish’ territory, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has moderated to ‘neutral’ from ‘bullish’ a day ago, after the selloff in software stocks.Trending Stocks To WatchIntel Corp (INTC):&nbsp;Semiconductor strength gains retail attention as CEO Lip-Bu Tan’s AI pivot bore fruit in INTC Q1 earnings. Its AI-driven business now represents 60% of Intel's revenue. Stock rose by more than 20% in early pre-market trading, with a sympathy rally across peers such as AMD (+8%).Rocket Lab (RKLB):&nbsp;Unveiled a new high-performance star tracker for high-radiation environments. This follows two space launches this week.&nbsp;Skillz (SKLZ)&nbsp;stock pared back nearly 30% in early pre-market trade. This followed a stellar 200% rally in the previous session due to a $420M legal victory against Papaya Gaming.&nbsp;Organon (OGN): The stock is trending on heavy volume following reports that India’s Sun Pharmaceutical is preparing a $13 billion all-cash binding offer to acquire the company.&nbsp;ASGN Inc (ASGN):&nbsp;The stock crashed 50% in early pre-market trade after a massive Q1 miss and skepticism over its ‘Everforth’ rebrand.Other tickers trending on Stocktwits&nbsp;at the time of writing included Lucid Group (LCID), ReAlloys Inc (ALOY), Oklo Inc (OKLO) and Nvidia (NVDA).Other Catalysts To WatchOn the economic front, traders will be watching the release of Durable Goods Orders (Mar) at 8:30 am ET.&nbsp;On earnings radar, watch out for quarterly reports from Procter &amp; Gamble ($PG - Cons: $1.56), Schlumberger ($SLB - Cons: $0.52), HCA Healthcare ($HCA - Cons: $7.15), and Norfolk Southern ($NSC) before the bell. Meanwhile, Charter Communications ($CHTR), Western Union ($WU) are among others reporting after market close today.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Mixed Despite AI-Fueled Intel Surge: Why AMD, RKLB, SKLZ, OGN, ASGN Are In Focus

Data from Stocktwits shows that retail traders stayed constructive on SPY but turned neutral on QQQ after a software-led pullback.

Equity

Data from Stocktwits shows that retail traders stayed constructive on SPY but turned neutral on QQQ after a software-led pullback.



ASGN (NYSE:ASGN) Hits New 12-Month Low After Analyst Downgrade

ASGN (NYSE:ASGN) Reaches New 52-Week Low Following Analyst Downgrade...

ASGN Q1 Earnings Call Highlights

ASGN (NYSE:ASGN) reported first-quarter 2026 revenue of $968.3 million, in line with both the prior-year period and company guidance, as executives emphasized continued demand for AI and data, cloud and infrastructure, and application engineering and modernization work. The quarter also marked a tra...

Wells Fargo & Company Issues Pessimistic Forecast for ASGN (NYSE:ASGN) Stock Price

Wells Fargo & Company lowered their target price on shares of ASGN from $54.00 to $33.00 and set an "equal weight" rating on the stock in a report on Thursday...

ASGN (NYSE:ASGN) Shares Gap Down After Earnings Miss

ASGN (NYSE:ASGN) Shares Gap Down Following Weak Earnings...

ASGN (NYSE:ASGN) Cut to Hold at Truist Financial

Truist Financial lowered shares of ASGN from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $60.00 to $33.00 in a report on Thursday...

Robert W. Baird Cuts ASGN (NYSE:ASGN) Price Target to $38.00

Robert W. Baird cut their target price on ASGN from $62.00 to $38.00 and set a "neutral" rating on the stock in a research note on Thursday...

ASGN (NYSE:ASGN) Lowered to "Market Perform" Rating by BMO Capital Markets

BMO Capital Markets downgraded shares of ASGN from an "outperform" rating to a "market perform" rating and set a $33.00 target price for the company. in a report on Thursday...

ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstockread more...

Why United Rentals Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

United Rentals (URI) stock rose in pre-market trading after reporting better-than-expected earnings and raising its FY26 sales guidance. Other gainers include PAPL, AKAN, YCBD, SST, MEHA, QS, BIVI...

$ASGN Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.13 down -72.92% YoY
• Reported revenue of $968.3M
• ASGN projects second quarter 2026 revenues between $970.0 million and $1,000.0 million, with diluted earnings per share estimated to range from $0.19 to $0.33. Gross margin is expected between 28.3% and 28.7%.

Stocktwits

ASGN Inc

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.13 down -72.92% YoY
• Reported revenue of $968.3M
• ASGN projects second quarter 2026 revenues between $970.0 million and $1,000.0 million, with diluted earnings per share estimated to range from $0.19 to $0.33. Gross margin is expected between 28.3% and 28.7%.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

ASGN Incorporated engages in the provision of information technology services and solutions. It operates through the Commercial and Federal Government segments. The Commercial segment involves the provision of consulting, creative digital marketing, and permanent placement services. The Federal Government segment provides mission-critical solutions. The company was founded on December 30, 1985 and is headquartered in Glen Allen, VA.

ASGN
ASGN Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Earnings Recap

ASGNASGN Inc